It may be possible to detect signs of Parkinson’s disease 20-30 years before symptoms appear, according to researchers in Australia. A biomarker called F-AV-133, used in combination with PET, or positron emission tomography, scans can help diagnose Parkinson’s disease and accurately track neurodegeneration, the researchers from the Florey Institute of Neuroscience and Mental Health, Melbourne, said.
F-AV-133 is an imaging agent and has shown promise as a PET tracer for detecting and monitoring neurodegeneration in Parkinson’s disease, a progressive neurological disorder characterised by tremor and impaired muscular coordination.
According to the researchers, the disease, often thought of as an illness of old age, in fact, starts in midlife and can go undetected for decades.
“Parkinson’s disease is very hard to diagnose until symptoms are obvious, by which time up to 85 per cent of the brain’s neurons that control motor coordination have been destroyed. At that point, many treatments are likely to be ineffective,” said Kevin Barnham, professor at The Florey and lead researcher of the study published in the journal Neurology.
In their study, 26 patients already diagnosed to have Parkinson’s disease and a control group of 12 people were scanned, along with 11 other people having Rapid Eye Movement sleep behaviour disorder (RBD), a strong indicator of the disease. All of them undertook two PET scans two years apart.
The researchers found that the PET scans showed a significant loss in the nerve cells or neurons in three key regions of the brain in individuals with the disease, even as no significant changes in their clinical symptoms were seen according to currently available diagnostic assessments. The findings suggest that F-AV-133 is a more sensitive means of monitoring neurodegeneration than what is now available, the researchers said in their study. Source: PTI